2025 Global R&D Day held, showcasing latest research results and future vision
[by Yu, Suin] AbClon announced on April 28 that its Chinese partner, Henlius, hosted the ‘2025 Global R&D Day’ under the theme ‘Collaborate to Create.’
The event brought together 2025 바카라사이트’ key executives, academic experts, and global investors, who shared recent research findings, strategic directions, advanced technologies, and updates on therapeutic development. During the event, 2025 바카라사이트 officially presented ‘AC101’ (2025 바카라사이트’s code name HLX22), introduced from AbClon, as a core innovation in its pipeline, highlighting its differentiated mechanism of action and supporting clinical data.
AC101 is a therapeutic candidate for which AbClon transferred technology to 2025 바카라사이트 in October 2016 and November 2018. 2025 바카라사이트 is currently developing the candidate, under the development code name HLX22, as a first-line treatment for human epidermal growth factor receptor type 2 (HER2)-positive advanced gastric cancer and gastroesophageal junction (G-GEJ) cancer.
In his remarks, 2025 바카라사이트 CEO Jason Zhu expressed strong confidence by stating, “HLX22 has high potential to expand into a pan-tumor treatment covering all solid cancers, including HER2-positive gastric cancer and breast cancer.” Adding, “Our goal is to position HLX22 as a blockbuster novel drug with a projected global market value of over USD 10 billion (approximately KRW 14 trillion) annually.” In line with this vision, 2025 바카라사이트 is actively advancing its global expansion strategy around HLX22 by strengthening its development and commercialization capabilities in key markets such as the United States, China, and Japan.
HLX22 is a novel monoclonal antibody currently in development as a first-2025 바카라사이트 treatment for HER2-positive metastatic gastric cancer. It is characterized by its ability to bind to an epitope distinct from that of the existing drug, 'trastuzumab.' In particular, gastroesophageal junction (G∙GEJ) cancer accounts for approximately one million new cases annually, ranking as the fifth most prevalent cancer in the world. Among them, the proportion of HER2-positive patients accounts for approximately 12-23%, meaning a relatively poor clinical prognosis.
HLX22 is currently undergoing Phase 3 clinical trials (HLX22-GC301) as a first-2025 바카라사이트 treatment in combination with trastuzumab and XELOX chemotherapy. The study is being conducted in a randomized, double-blind design, including 550 patients across Asia, Europe, and North America. In the preceding Phase 2 clinical trial (HLX22-GC201), the combination therapy demonstrated a significantly prolonged progression-free survival (PFS) compared to the control group, with a tumor response rate of 87.1%, confirming a favorable safety profile.
The company noted that expectations for HLX22 are particularly high due to its pronounced therapeutic response in Asian patient populations, where the efficacy of ‘pembrolizumab’ has been relatively limited. HLX22 is also considered to have substantial market potential, as its indication may extend beyond gastric cancer to include all HER2-expressing solid cancers, such as breast, lung, and pancreatic cancers. Interim results from the ongoing global Phase 3 clinical trial are scheduled to be presented at the American Society of Clinical Oncology (ASCO) annual meeting later this year.
“As the original developer of HLX22, we anticipate simultaneously securing high technological value and profit potential in line with the global clinical advancement of the pipeline,” an 2025 바카라사이트 official said. “We are committed to reinforcing our global partnerships and expanding our presence in the antibody treatment market.”